Dade Behring公司從美國(guó)Cleveland診所獲得如下授權(quán)：將髓過(guò)氧化物酶自動(dòng)檢測(cè)商品化的特定半獨(dú)有權(quán)利。

根據(jù)Cleveland診所進(jìn)行的研究發(fā)現(xiàn)：髓過(guò)氧化物酶檢測(cè)對(duì)發(fā)病時(shí)肌鈣蛋白A低水平（通常提示心肌細(xì)胞沒(méi)有死亡）的胸痛患者特別有診斷價(jià)值。在這種情況下，髓過(guò)氧化物酶水平升高與隨后發(fā)生的心臟病有聯(lián)系。因此簡(jiǎn)單的MPO檢測(cè)有助于醫(yī)生鑒別出那些隨后可能心臟病發(fā)作的患者，從而指導(dǎo)他們?cè)谛呐K病發(fā)作之前開(kāi)始治療。

Cleveland診所的研究人員對(duì)急診室里主訴胸痛的600多位患者的初始髓過(guò)氧化物酶水平進(jìn)行了研究。通過(guò)髓過(guò)氧化物酶檢測(cè)以及其它相關(guān)實(shí)驗(yàn)室風(fēng)險(xiǎn)評(píng)估，研究人員把預(yù)測(cè)患者發(fā)病后30天～6個(gè)月出現(xiàn)心臟問(wèn)題的能力，從54%提高至85％。在歐洲完成的一項(xiàng)較大規(guī)模的研究證實(shí)了這些結(jié)果。

Cleveland診所心血管科主任Eric J. Topol醫(yī)學(xué)博士說(shuō)：“一項(xiàng)簡(jiǎn)單的血液檢測(cè)就能夠幫助醫(yī)生鑒別出存在心臟損害危險(xiǎn)的患者是令人興奮的，我們需要建立肌鈣蛋白的檢測(cè)來(lái)改變醫(yī)學(xué)發(fā)展現(xiàn)狀，髓過(guò)氧化物酶檢測(cè)或許是達(dá)到這個(gè)目標(biāo)的途徑之一。”

Dade Behring to Develop Cardiac Marker Tests
 
Certain semi-exclusive diagnostic rights for the commercialization of automated diagnostic tests using myeloperoxidase (MPO) have been granted to Dade Behring (Deerfield, IL, USA) by The Cleveland Clinic (OH, USA).

According to research conducted at The Cleveland Clinic, MPO testing may be particularly beneficial in patients with chest pain who exhibit low initial troponin (a) levels, usually an indication that no heart muscle cells have died. In this case, the presence of an elevated MPO level has been linked to risk for subsequent cardiac events. Therefore, a simple MPO blood test has the potential to help doctors identify patients at risk of subsequent heart attack and refer them for treatment prior to the occurrence of heart damage.

Researchers at the Cleveland Clinic investigated initial MPO levels in more than 600 patients in the emergency room complaining of chest pain. By using an MPO blood test in addition to laboratory-based risk assessments, they increased their ability to identify patients who would have heart problems during the next 30 days to six months from 54% to 85%. A larger study in Europe has confirmed these results.

“The potential of a simple blood test to help identify patients at particular risk of heart damage is very exciting,” commented Eric J. Topol, M.D., chairman of The Cleveland Clinic’s department of cardiovascular medicine. “We need to build on the great success of the troponin test in changing medicine, and the MPO test may be a way to do that.”